Jeannette H. Lee was a distinguished American biostatistician and academic, widely recognized for her seminal contributions to the design and analysis of clinical trials, particularly in oncology. She was a Professor Emerita in the Department of Biostatistics at the University of Alabama at Birmingham (UAB) School of Public Health.
Career and Contributions Lee's career was primarily dedicated to advancing statistical methodologies for medical research, with a significant focus on cancer clinical trials. She spent several decades at UAB, where she held various leadership roles and was instrumental in developing the university's biostatistics program.
Her work had a profound impact on the conduct of multi-institutional clinical trials, especially those sponsored by the National Cancer Institute (NCI) and its cooperative groups. She was a long-standing member and influential statistician for SWOG (formerly the Southwest Oncology Group), one of the largest NCI-funded cancer research cooperative groups. In this role, she provided crucial statistical oversight for numerous groundbreaking cancer treatment trials, helping to translate scientific discoveries into improved patient care.
Lee was particularly known for her expertise in adaptive clinical trial designs, which allow for modifications to trial parameters based on accumulating data, making trials more efficient and ethical. She published extensively on these and other statistical methods, contributing significantly to the biostatistical literature. Beyond her research, she was a dedicated educator and mentor, guiding countless students and junior faculty members in the field of biostatistics.
Awards and Recognition Throughout her career, Lee received numerous accolades for her contributions to biostatistics and public health. These recognitions underscored her impact on clinical research and her leadership within the scientific community.
Legacy Jeannette H. Lee's legacy endures through her innovative statistical methodologies, the successful clinical trials she helped design, and the many biostatisticians she mentored. Her work has significantly advanced the methodology of clinical trials, particularly in oncology, and has left a lasting mark on cancer research. She passed away in 2021.